Homepage
Author:
Cartesian Therapeutics, Inc.
Posted Date:
June 9, 2026
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases
Cartesian Therapeutics, Inc.
June 9, 2026
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Cartesian Therapeutics, Inc.
May 26, 2026
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Cartesian Therapeutics, Inc.
May 12, 2026
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc.
May 4, 2026
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Cartesian Therapeutics, Inc.
April 30, 2026
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc.
April 2, 2026
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
Cartesian Therapeutics, Inc.
March 9, 2026
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Cartesian Therapeutics, Inc.
February 23, 2026
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, Inc.
February 3, 2026
